药物干预对慢性阻塞性肺疾病合并症的临床研究

《药物干预对慢性阻塞性肺疾病合并症的临床研究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、药物干预对慢性阻塞性肺疾病合并症的临床研宄［摘要］目的探讨不同药物干预对慢性阻塞性肺疾病（COPD）合并症的临床治疗效果。方法选取2014年9月〜2015年12月本院诊治的120例COPD稳定期患者作为研究对象，根据治疗措施将其分为4组，各30例。对照组给予噻托溴铵吸入剂治疗，阿托伐他汀治疗组给予阿托伐他汀口服联合噻托溴铵吸入治疗，沙美特罗氟替卡松吸入剂治疗组给予沙美特罗氟替卡松联合噻托溴铵吸入治疗，美托洛尔治组给予美托洛尔片口服联合噻托溴铵吸入治疗。比较半年后各组的肺功能、CAT及mMRC评分、急性加重期次数、全身合并症（心血管、骨骼肌萎缩、骨质疏松、郁抑症等）

2、治疗效果。结果沙美特罗氟替卡松吸入剂治疗组的肺功能指标显著高于对照组，差异有统计学意义（P0.05）。沙美特罗氟替卡松吸入剂治疗组及美托洛尔片治疗组的症状评分显著低于对照组，半年间急性加重期次数显著少于对照组，差异有统计学意义（P0.05）。阿托伐他汀组及美托洛尔片组的心血管合并症治疗有效率显著高于对照组与沙美特罗氟替卡松吸入剂治疗组，差异有统计学意义（P0.05）。结论使用多种药物联合治疗COPD稳定期患者可能取得疾病本身及合并症治疗的最佳疗效。［关键词］药物干预；慢性阻塞性肺疾病；合并症;治疗效果［中图分类号］R563［文献标识码］A［文章编号］1674-47

3、21(2016)07(b)-0021-04［Abstract］ObjectiveToexploretheclinicaleffectofdifferentdruginterventiononchronicobstructivepulmonarydiseases(COPD).Methods120caseswithCOPDinthestableperiodfromSeptember2014toDecember2015inourhospitalwereselectedanddividedinto4groupsaccordingtothetreatmentmeasures

4、，30casesineachgroup.Thecontrolgroupwasgiventiotropiumbromideinhalationtherapy,theatorvastatintreatmentgroupwastreatedwithatorvastatinoraltherapycombinedwithtiotropiumbromideinhalationtherapy，thesalmeterolandfluticasonetreatmentgroupwasgivensalmeterolandfluticasonecombinedwithtiotropiu

5、mbromideinhalationtherapy,themetoprololtreatmentgroupwasgivenmetoprololtabletoraltherapycombinedwithtiotropiumbromideinhalationtherapy.Lungfunction，catandmMRCscores，acuteexacerbationfrequency，thetherapeuticeffectofsystemiccomorbidities(cardiovascularandskeletalmuscleatrophy，osteoporos

6、is，depressionandother)ineachgroupwithinhalfayearwascompared.ResultsThepulmonaryfunctionindexofthesalmeterolandfluticasonetreatmentgroupwashigherthanthatofthecontrolgroup，withsignificantdifference(P0.05).Thesymptomscoreinthesalmeterolandfluticasonetreatmentgroupandthemetoprololtreatmen

7、tgroupwaslowerthanthatinthecontrolgroup，acuteexacerbationfrequencywithinhalfayearinthesalmeterolandfluticasonetreatmentgroupandthemetoprololtreatmentgroupwaslessthanthatinthecontrolgroup，withsignificantdifference(P0.05).Thetherapeuticeffectiverateofcardiovascularcomplicationsoftheator

8、vasta